

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
19 March 2020 (19.03.2020)



(10) International Publication Number
WO 2020/052677 A1

(51) International Patent Classification:

A61K 47/64 (2017.01) A61P 17/00 (2006.01)
C07K 2/00 (2006.01) A61P 29/00 (2006.01)

(21) International Application Number:

PCT/CN2019/105832

(22) International Filing Date:

14 September 2019 (14.09.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/CN2018/105703

14 September 2018 (14.09.2018) CN

PCT/CN2018/119072

04 December 2018 (04.12.2018) CN

(71) Applicant: **JIANGYIN USUN PHARMACEUTICAL CO., LTD.** [CN/CN]; B13, No.2 Dongsheng West Road, Jiangyin, Jiangsu 214437 (CN).

(72) Inventors: **SAMUELSSON, Bengt Ingemar**; Scheeles Vag 2, Scheelelaboratoriet, Hus A4, Plan 4, SE-171 77 Stockholm, Sweden (SE). **GU, Ming**; Jiangyin Bengt I. Samuelsson Institute Of Life Science Co., Ltd., B13, No.2 Dongsheng West Road, Jiangyin, Jiangsu (CN).

(74) Agent: **WU, FENG & ZHANG**; 3FL, Building 2, Yard 3, FengXiuZhongLu Road, Haidian District, Beijing, Beijing 100094 (CN).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,


MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: NEW CONJUGATES OF MONTELUKAST AND PEPTIDES



(57) Abstract: There is provided a peptide-containing compound that comprises a peptide component which is an amino acid sequence of from 2 to 45 amino acids, which peptide component is covalently bonded to one or more compounds of the formula (I), wherein: R¹ is selected from the group consisting of -C(CH₃)₂OH, -COCH₃, -C(CH₃)=CH₂ and -C(CH₃)₂H; and n is 0, 1 or 2, as well as regioisomers, stereoisomers, and pharmaceutically- or cosmetically-acceptable salts of said peptide-containing compound. The compound of formula I is preferably montelukast, montelukast styrene or hydrogenated montelukast styrene. The peptide-containing compound is particularly useful in the treatment of inflammation, including wounds, hemorrhoids, burns, psoriasis, acne, atopic dermatitis, allergic rhinitis, allergic conjunctivitis, chronic obstructive pulmonary disease, inflammatory bowel disease (such as ulcerative colitis). The peptide-containing compound is also useful in the treatment of idiopathic pulmonary fibrosis.

WO 2020/052677 A1